. . . . . . . . . . . . . . "gtp(p(MGI:Hras)) -> path(SDIS:\"Doxorubicin resistance\")" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "20131211" . "Both ras- and trk-transformed cell lines were less sensitive to cisplatin (CDDP) and doxorubicin (DXR) than the wild type. " . . "Selventa" . . . . "2014-07-03T14:33:49.789+02:00"^^ . . .